Investigation Alert: Bernstein Litowitz Berger & Grossmann LLP Announces Investigation of Annovis Bio, Inc. and Encourages Investors to Contact the Firm

NEW YORK, July 30, 2021 /PRNewswire/ -- Prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") is investigating potential violations of the federal securities laws by Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE American: ANVS).

Updated Full Logo

BLB&G is investigating whether Annovis misled investors regarding the efficacy of its Alzheimer's drug, Posiphen.

Annovis is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. The Company's lead candidate is Posiphen, or ANVS401, an orally administered drug that purportedly inhibits the production of neurotoxic proteins that lead to neurodegeneration. Annovis is currently testing Posiphen in two Phase 2 clinical trials for the treatment of Alzheimer's Disease and Parkinson's Disease.

BLB&G's investigation is focused on whether Annovis misled investors about Posiphen's efficacy in treating patients with Alzheimer's and Parkinson's Diseases.

On July 28, 2021, after the market closed, Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer's and Parkinson's Disease patients relative to a placebo.  On this news, Annovis' stock price declined $65.94 per share, or over 60%.

The investigation is being led by BLB&G partners Avi Josefson and Scott R. Foglietta. Annovis investors who suffered a loss and would like to learn more about our investigation, please contact BLB&G at (212) 554-4444, via e-mail at inquiries@blbglaw.com, or through the form on our website at https://www.blbglaw.com/cases-investigations/annovis-bio-inc.

About BLB&G

BLB&G is widely recognized worldwide as a leading law firm advising institutional investors on issues related to corporate governance, shareholder rights, and securities litigation.  Since its founding in 1983, BLB&G has built an international reputation for excellence and integrity and pioneered the use of the litigation process to achieve precedent-setting governance reforms. Unique among its peers, BLB&G has obtained several of the largest and most significant securities recoveries in history, recovering over $33 billion on behalf of defrauded investors. More information about the firm can be found online at www.blbglaw.com.

This press release may be considered Attorney Advertising under the applicable law and ethics rules of some jurisdictions. Prior results do not guarantee a similar outcome.

Contact
Avi Josefson
Scott R. Foglietta
Bernstein Litowitz Berger & Grossmann LLP
1251 Avenue of the Americas, 44th Floor
New York, New York 10020
(212) 554-4444
inquiries@blbglaw.com          

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-alert-bernstein-litowitz-berger--grossmann-llp-announces-investigation-of-annovis-bio-inc-and-encourages-investors-to-contact-the-firm-301344991.html

SOURCE Bernstein Litowitz Berger & Grossmann LLP

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.